CurveBeam AI Limited

A$0.02As of Sun 8 Nov 2026, 12:00 UTC

ASX:CVBHealthcare

Country Australia

PE (Fwd) •••

TSR 3Y CAGR (64.42%)

Div yield —

ROE (59.88%)

Medical Devices

Beta (5Y) 1.77

PE TTM —

TSR TTM (81.11%)

Mkt cap A$13.06M

ROIC (21.77%)

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$0.0212

24.83%

(82.06%)

Hold 7|12|3|1|4

TTM

FYE 30 Jun AUD

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

5Y

10Y

Peers

0.590

Revenue$M

2.007

2.126

2.271

2.423

2.538

2.604

2.712

2.842

2.974

3.086

0.621

3.99%

4.90%

48

20.70

Revenue growth%

8.12

7.33

5.56

4.79

4.41

3.20

0.40

0.40

0.40

0.40

22.44

0.40

3.81

23

15.71

Gross margin%

0.40

2.83

4.97

3.96

2.20

4.34

5.86

4.57

3.79

3.64

13.31

4.34

3.87

85

22.16

Operating margin%

12.86

9.93

7.07

7.13

6.66

3.81

3.08

4.77

7.47

9.47

14.48

4.77

7.10

40

11.94

Net margin%

27.45

27.78

27.67

27.93

30.34

28.26

26.19

25.25

24.67

25.60

14.56

25.60

27.56

23

27.81

P/E ratio (avg)x

19.31

20.55

23.36

24.55

25.45

27.45

29.85

32.05

33.23

30.64

14.74

30.64

26.45

45

19.34

EV/EBITx

30.53

26.50

23.37

20.22

20.81

21.77

21.16

23.01

23.92

24.02

9.709

23.01

23.19

12

29.89

FCF yield (avg)%

25.64

22.95

24.91

27.04

25.20

26.79

29.20

30.80

32.83

34.07

28.92

30.80

26.92

36

11.42

FCF margin%

13.38

11.76

9.43

9.09

10.83

7.83

9.27

9.13

8.41

10.39

10.96

9.13

9.35

75

0.537

FCF / Net incomex

1.137

0.999

0.926

0.909

0.951

1.018

0.965

0.897

0.970

0.924

1.033

0.965

0.958

53

15.95

ROIC%

7.53

7.39

7.07

5.96

7.46

6.21

7.08

10.05

8.12

9.96

24.09

8.12

7.43

82

20.67

Return on equity%

25.00

26.94

28.56

31.13

31.03

28.98

29.16

26.88

27.37

29.21

23.76

28.98

28.77

89

22.35

Return on assets%

25.42

26.92

26.40

27.13

27.21

27.23

24.54

27.34

28.41

27.78

27.38

27.34

27.17

41

—

EPS$

—

—

—

—

—

—

—

—

—

—

—

4.65%

2.68%

—

4.40

EPS growth%

12.84

14.34

15.00

13.77

14.58

16.57

16.00

14.76

13.31

12.99

27.26

14.76

14.46

82

—

Bookvalue per sh$

—

—

—

—

—

—

—

—

—

—

—

2.43%

1.69%

—

—

FCF per share$

—

—

—

—

—

—

—

—

—

—

—

(3.68%)

(1.85%)

—

—

Dividend per sh$

—

—

—

—

—

—

—

—

—

—

—

4.68%

4.42%

—

3.47

Div yield (avg)%

10.35

10.49

9.64

7.90

5.99

5.51

5.37

4.47

7.34

10.08

8.86

5.51

7.62

72

4.24

Payout ratio%

12.81

10.42

8.87

7.01

9.50

10.79

13.67

11.51

9.11

9.16

16.99

10.79

9.96

9

756.5

Shares (diluted)M

939.1

996.3

940.0

954.7

926.6

848.7

762.4

729.2

807.4

766.0

782.8

(3.74%)

(2.34%)

11

26.42

Buyback yield%

9.65

10.74

10.26

9.60

9.06

7.47

5.71

3.53

5.81

4.78

23.17

5.71

8.26

42

1.286

D/E ratiox

0.441

0.479

0.495

0.544

0.479

0.449

0.409

0.355

0.360

0.398

0.983

0.398

0.445

41

2.109

Enterprise value$M

1.330

1.359

1.463

1.497

1.569

1.349

1.281

1.385

1.434

1.249

0.587

(4.46%)

0.09%

37

0.151

LT debt$M

4.132

4.405

5.192

5.517

5.787

6.263

7.330

8.263

8.037

7.802

2.729

6.16%

6.85%

35

Peers (US$8.968M)

Cap (US$)

PE

Atomo Diagnostics…

9.297M

—

Memphasys Limited

8.503M

—

ImpediMed Limited

7.546M

—

8.886M

—

Capital

TTM

5Y

10Y

Leveragex

0.384

0.103

0.104

EBIT/Intx

0.191

0.637

0.691

Own earn%

38.38

(107.67)

(79.27)

Sh yield%

29.89

12.98

14.95

Owners

Insiders/Inst%

2.38

21.11

Short interest%

4.26

SBC / revenue%

2.97

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

12

Op margin range%

3–13

$1 testx

—

Incr. ROIC%

17

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$3.086M

4.90%

1.00×

Cost of revenue

$1.885M

5.07%

1.02×

Operating expenses

$0.379M

4.99%

1.01×